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 A B S T R A C T 
 POSTER PRESENTATIONS 
 Advances in Pain Management 
 Buffered dextrose 5% – an alternative analgesia 
 M. L. Swee 1  , H. E. Liu 1 , Y. Y. Jasmine Sze 1 , H. N. Kooi 1 , H. C. Siew 1 , 
S. Shantene 1 , M. Nadiah 1 , M. Asmah 1 , C. G. Suk 1  
 1 Hospital Tuanku Ja ' afar Seremban, Seremban, Malaysia 
 Background/Purpose: Chronic pain around neck and upper limbs 
(NUL) among patients with rheumatic and musculoskeletal disease 
(RMD) is challenging to handle. Dr John Lyftogt has established the 
use of buffered dextrose 5% with pH of 7.4 (BD5%) in Perineural 
injection therapy (PIT) to treat such condition with success. 
 Our primary objective is to assess pain score reduction (PSR) in 
Numerical Rating scale (NRS) after PIT in this region. Secondary ob-
jective is to assess percentage of patients who achieved at least 50% 
PSR at the end of treatment. 
 Methods: Patients with NUL pain who received PIT in 2019 and 
had followed up for 12 months were reviewed. PIT was performed 
by serial injection of BD5% along the superficial nerve(s) under-
neath the skin using 30G, 1cm hypodermic needle. Patients with 
pain score not recorded or still undergoing PIT were excluded. 
PSR before and after series of treatments were analysed using 
paired T test. 
 Results: 21 patients with NUL pain were treated with total of 61 PIT. 
Mean age was 58.1. 76.2% (n = 16) were female. 57.1% (n = 12) had 
shoulder tendinopathy with or without tear, 33.3% (n = 7) had fibro-
myalgia while 9.5% (n = 2) had cervical spondylosis. 
 Baseline pain score was 7.0 ± 1.4, duration of pain was 1.8 ± 1.6 
years. Average 2.9 ± 1.5 times of PIT were performed. 19% (n = 4) 
had one PIT, 23% (n = 5) needed two while 29% (n = 6) needed three 
PIT. Distribution of cases according to number of PIT as shown in 
Figure 1. 
 Pain score reduced to 2.9 ± 1.7, 2.1 ± 1.4 and subsequently 1.4 ± 1.1 
following first, second and third PIT. On average, PSR was 6.0 ± 2.2 
(p = 0.0001). The effect lasted for 5.7 ± 4.2 months. No complica-
tions were observed. 
 100% of them demonstrated 50% or more PSR. 
 Conclusion: Buffered dextrose 5% in perineural injection therapy al-
leviates NUL pain significantly. This is a good and safe alternative 
treatment for RMD patients with NUL pain. 
 Buffered dextrose 5% - the sweet solution for 
chronic low back pain 
 M. L. Swee 1  , S. Shantene 1 , H. E. Liu 1 , Y. Y. Jasmine Sze 1 , H. N. Kooi 1 , 
H. C. Siew 1 , M. Nadiah 1 , M. Asmah 1 , C. G. Suk 1  
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 Background/Purpose: Chronic low back pain (CLBP) is one of the 
constant struggle among patients with rheumatic and musculoskel-
etal disease (RMD). Dr John Lyftogt had used buffered dextrose 5% 
with pH of 7.4 (BD5%) via caudal epidural injection (CEI) to treat 
CLBP successfully. 
 Our primary objective is to assess pain score reduction (PSR) in 
Numerical Rating scale (NRS) after CEI. Secondary objective is to 
assess percentage of patients who achieved at least 50% PSR at the 
end of treatment. 
 Methods: Patients with CLBP who received CEI in 2019 and had fol-
lowed up for 12 months were reviewed. CEI was performed by giv-
ing 10 mL of BD5% at caudal epidural region via 26G, 1cm needle. 
Patients with pain score not recorded or still undergoing CEI were 
excluded. PSR before and after series of treatments were analysed 
using paired T test. 
 Results: 35 patients received total of 127 CEI for CLBP. Mean age 
was 62.1 years and 80% (n = 28) were females. 80% (n = 28) had 
mechanical low back pain due to spondylosis, prolapsed interver-
tebral disc, spinal stenosis and spondylolisthesis. 14.3% (n = 5) had 
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 Fatal gastrointestinal manifestations of SLE: case 
reports 
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 Background: SLE- related gastrointestinal involvement such as gas-
trointestinal vasculitis and thrombosis are clinically important, as it 
could progress to life- threatening outcome if not treated promptly. 
We describe 2 patients who were admitted to our hospital with fatal 
gastrointestinal manifestations of SLE. 
 Method: Case Report. 
 Results: Case 1: The patient was a 24- year- old Asian woman who 
was diagnosed with SLE in 2014 and class IV lupus nephritis in 
2018. She presented with hypovolemic shock secondary to mas-
sive hematochezia. CT abdomen and angiography revealed multi-
ple bleeding sites in jejunum and mesenteric vasculitis changes of 
the bowels. Gastroduodenoscopy and CT angioembolization of the 
mesenteric arteries were performed to stop the bleeding, and IV 
Methylprednisolone, IV Cyclophosphamide, IV Rituximab were ad-
ministered. Eventually she succumbed to Transfusion- Related Acute 
Lung Injury (TRALI) from multiple blood transfusions. 
 Case 2: The patient was a 61- year- old male smoker who was diag-
nosed with SLE with lupus nephritis in April 2020. He however re-
fused renal biopsy or cyclophosphamide. He presented a few months 
later with fever and colicky abdominal pain for 2 days. A diagnosis of 
Superior Mesenteric Artery (SMA) Thrombosis with Bowel Ischemia 
was made, which was likely due to Catastrophic Anti- Phospholipid 
Syndrome (CAPS) with SLE, based on CT abdomen findings of SMA 
thrombosis, bilateral common femoral vein thrombosis and multiple 
splenic infarcts. Heparin infusion was initiated, and he was admin-
istered IV Methylprednisolone and Intravenous Immunoglobulin 
(IVIg). He developed Disseminated Intravascular Coagulation (DIVC) 
subsequently and succumbed to his illness at day 2 of admission. 
 Conclusion: In summary, early diagnosis with prompt and adequate 
treatment of gastrointestinal manifestation of SLE is essential to 
avoid serious complications like haemorrhage or perforation with a 
high mortality rate. 
 Posterior reversible encephalopathy syndrome 
in patients with systemic lupus erythematosus 
following methylprednisolone pulse therapy 
 D. Marcos 1  , M. Tee 1  
 1 Division of Rheumatology, Department of Medicine, University of the 
Philippines- Philippine General Hospital, Manila, Philippines 
 Background/Purpose: Methylprednisolone Pulse Therapy (MPPT) is 
one the treatment strategies used to control high disease activity of 
SLE. The occurrence of Posterior Reversible Encephalopathy (PRES) 
upon completion of MPPT regimen has been described in literature. 
The timing of onset of PRES has varied among different literature. 
Through this report, we aim to increase awareness that PRES can 
occur even after the 1 st  dose of MPPT. 
 Methods: Case Report 
 Results: We present 2 patients with active SLE who developed 
PRES after the first MPPT dose. The first patient is a 19- yo fe-
male diagnosed with SLE who presented with crampy abdominal 
pain for 1 week. Upon diagnostic evaluation, she was diagnosed to 
have mesenteric vasculitis and lupus nephritis. She was given 1 gm 
MPPT. Recurrent seizures were noted following the 1 st  MPPT dose. 
Electroencephalogram (EEG) and MRI studies showed hyperintense 
signals in the parietal, temporal and occipital lobes. The diagnosis 
of PRES was made. Our second patient is a 35- yo female patient 
with SLE who presented with generalized tonic clonic seizures upon 
admission. Following the first dose of MPPT, she sudden blurring 
of vision in the left eye which rapidly progressed to left monocular 
blindness. She was diagnosed to have PRES following the demon-
stration of hypodensities in the right parietal and bilateral temporal 
lobes on Contrast enhanced CT. Clinical recovery for both patients 
has been satisfactory following strict control of blood pressure and 
individualized immunosuppression regimens. 
 Conclusion: These 2 cases demonstrate the occurrence of PRES fol-
lowing MPPT as early as the 1 st  dose. 
 Clinical features and treatment outcome of 
neuropsychiatric lupus (NPSLE): a single centre 
experience 
 A. Masnammany 1 , A. Bhullar 1 , A. Mohamed Ismail 1 , O. Seok Ling 1  
 1 Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia 
 Introduction: NPSLE encompasses neurologic and psychiatric mani-
festations involving the central (CNS) and peripheral nervous sys-
tems (PNS). 
 Objective: To identify patient characteristics, clinical features, 
SLEDAI, treatment protocol and outcome of patients with NPSLE. 
 Methodology: A retrospective, observational single centre study of 
all patients (n = 20) admitted for NSPLE from Dec 2017 to Dec 2019 
in Hospital Raja Perempuan Zainab II. Neurological outcome was de-
termined based on 3 and 6 months follow up . 
